Publications by authors named "Joseph Toerner"

Claim this Profile
A
Author Correction: Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization.
Yugenia K Hong-Nguyen, Joseph Toerner, Lucia Lee, Maria C Allende, David C Kaslow

NPJ Vaccines· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization.
Yugenia K Hong-Nguyen, Joseph Toerner, Lucia Lee, Maria C Allende, David C Kaslow

NPJ Vaccines· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.
Frank A Anania, Lara Dimick-Santos, Ruby Mehta, Joseph Toerner, Julie Beitz

Hepatology· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardizing Safety Assessment and Reporting for Neonatal Clinical Trials.
Jonathan M Davis, Gerri R Baer, Susan McCune, Agnes Klein, Junko Sato, Joseph Toerner

J Pediatr· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and physician attitudes regarding risk and benefit in streamlined development programmes for antibacterial drugs: a qualitative analysis.
Thomas L Holland, Stephen Mikita, Diane Bloom, Jamie Roberts, Jonathan McCall, Joseph Toerner

BMJ Open· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing New Antibacterial Drug Development for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia.
Joseph G Toerner, Daniel Rubin

Clin Infect Dis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Commentary: A Collaborative Model for Endpoint Development: Advancing the Science of Antibacterial Drug Clinical Trials.
Joseph G Toerner, Edward Cox

Clin Infect Dis· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.
Dakshina Chilukuri, Owen McMaster, Kimberly Bergman, Philip Colangelo, Kerry Snow, Joseph G Toerner

Clin Infect Dis· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Joseph G Toerner, Laurie Burke, Scott Komo, Elektra Papadopoulos

Clin Infect Dis· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human papillomavirus vaccine.
Nancy B Miller, Gopa Raychaudhuri, Joseph G Toerner

N Engl J Med· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kawasaki-like syndrome: abacavir hypersensitivity?
Joseph G Toerner, Therese Cvetkovich

Clin Infect Dis· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis